Contents

Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension (LUNAR)

August 1, 2016

Clinical trial

Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.

Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN

Am J Ophthalmol. 2016 Aug;168:250-259.
Full text | Metrics.

Main finding: Latanoprostene bunod ophthalmic solution 0.024% every evening demonstrated significantly greater IOP lowering than timolol 0.5% BID at all but the earliest time point (8am) evaluated over 3 months of treatment in patients with open-angle glaucoma or ocular hypertension.

 

  • Purpose: To compare the IOP-lowering effects of Latanoprostene bunod vs timolol in patients with open-angle glaucoma or ocular hypertension.
  • Study type: Randomized controlled trial
  • Condition: Open angle glaucoma, Ocular Hypertension

Participants:≥18 years old, open angle glaucoma or ocular hypertension

 

  • n=387 patients

 

Intervention:

 

Group 1: latanoprostene bunod (LBN) ophthalmic solution 0.024% every evening
Group 2: Timolol 0.5% bd

Mean IOP reduction in the LBN group was significantly greater than timolol at all but the first time point in this study (week 2, 8 AM).

 

 

Outcomes LBN 0.024% Timolol 0.5%
Proportion of subjects with mean IOP ≤18 mmHg 17.1% 11.1%
Proportion of subjects with IOP reduction ≥25% 31.0% 18.5%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed